# Study of Ulevostinag (MK-1454) Alone or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001)

> **NCT03010176** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 156 (actual)

## Conditions studied

- Solid Tumors
- Lymphoma

## Interventions

- **DRUG:** Ulevostinag
- **BIOLOGICAL:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03010176
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-02-03
- **Primary completion:** 2022-04-21
- **Final completion:** 2022-04-21
- **Target enrollment:** 156 (ACTUAL)
- **Last updated:** 2025-10-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03010176

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03010176, "Study of Ulevostinag (MK-1454) Alone or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03010176. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*